CTLA4 and melanoma: These are: autologous TILs administered in conjunction with interleukin-2 following a lymphodepleting preparative regimen [4,9], while the others are based on the enhancement of the immune system function by blockade of the cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) by the monoclonal antibody ipilimumab which is at the present approved by the United States Food and Drug Administration (FDA) for use in patients with unresectable melanoma [6,7,10].